Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2011 | 2012 | 2013 | |
|---|---|---|---|
| Revenue | $563.4K | $471.3K | $399.2K |
| Cost of revenue | $221.5K | $216.1K | $107.7K |
| Gross profit | $341.9K | $255.2K | $291.4K |
| Gross margin | 60.7% | 54.2% | 73.0% |
| R&D | $0 | $0 | $0 |
| Operating income | −$29.9K | −$7.9K | $32.9K |
| EBITDA | −$29.4K | −$7.0K | $35.8K |
| Net income | −$57.2K | −$32.6K | $15.6K |
| Net margin | -10.2% | -6.9% | 3.9% |
| EPS (diluted) | -0.00 | -0.00 | 0.00 |
Annual figures · source: Financial Modeling Prep
NEUROGENESIS INC
No one on the platform currently holds NEUN.
No tracked institution reports a position in NEUN as of their last filing.
No one on the platform has traded NEUN yet.
| $8180 |
| — |
| KKURChromoCure, Inc. | $0.00 | +0.00% | $8200 | — |
| SAGDSouth American Gold Corp. | $0.00 | +0.00% | $67735 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.